1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Advanced Micro Devices' Radeon R9 295X2 Is Beastly Good For Gamers And Litecoin Miners


      Wed, 9 Apr 2014

      release review of this GPU. The reviewer, Ryan Smith, called the R9 R295X2 "beastly good" and a winner-by-default. Smith said the AMD GPU will do well because the $3,000 price tag of the Nvidia GTX Titan Z will be in a Complete Story »

    2. GTx CEO Mitch Steiner steps down


      Fri, 4 Apr 2014

      GTx ( GTXI ) says CEO, Vice Chairman and co-founder ..... Hanover has served as president and COO since GTx 's inception in September 1997. SA contributor Cora Schlesinger has been bullish on GTx since April 2013, when it traded at almost

    3. Nvidia details next-gen GPU platform, announces $3K card


      Tue, 25 Mar 2014

      solution (relies on Nvidia's Kepler architecture) that will retail for a whopping $3K. Nvidia's current flagship (the GTX Titan Black) only goes for $999, and AMD 's top-of-the-line R9 290X ( previous ) has a $549 MSRP. Nvidia has been

    4. Nvidia launches new notebook GPUs, promises big battery life gains


      Wed, 12 Mar 2014

      s new Maxwell architecture on the low-end, and its older Kepler architecture on the high-end. The top-of-the-line GTX 880M (competes against AMD 's R9 M290X ) features 1536 cores, a 954MHz. GPU clock, and a 256-bit GDDR5 graphics RAM interface

    5. When Flexibility Meets Opportunity in the European Commercial Real Estate Market


      Wed, 13 Nov 2013

      We are raising GTx 's fair value on recent positive Phase II trial results for Ostarine.

    6. America: The New Europe?


      Wed, 2 Oct 2013

      GTx adds a European partner.

    7. GTx muscle drug fails late-stage trials, shares plunge


      Mon, 19 Aug 2013

      (Reuters) - GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value...

    8. Dropping Coverage of GTx


      Sun, 24 Oct 2010

      We're dropping coverage of GTx Inc GTXI to focus our resources elsewhere.

    9. Drug Development Moves Along at GTx


      Fri, 17 Sep 2010

      GTx Inc. GTXI reported second-quarter results that came ..... treatment for advanced prostate cancer, GTx -758, met endpoints in a Phase II study ..... Administration, and will continue to push ahead on GTx 758. In the meantime, GTx continues to

    10. New Morningstar Analyst Report - GTx , Inc.

      Stock Reports

      Wed, 9 Jun 2010

      generate substantial revenue . Acapodene is GTx 's first in - house drug candidate . The ..... traction with urologists or oncologists . GTx may not have success in repartnering Ostarine ..... large potential patient population . If GTx can establish another partnership or independently

    « Prev1234Next »
    Content Partners